Entrectinib, which targets NTRK fusions while also simultaneously targeting ALK and ROS1 fusion proteins, was approved the following year. More recently, Doz et al. reported on 33 central nervous system tumors, including both high-grade and low-grade glioma, treated with larotrectinib [8]. This evidence concerns the gene ROS1 and glioma.